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Abstract
Background and Purpose: Acute stroke has a high morbidity and mortality. We evaluated the predictive value of adrenal
function testing in acute ischemic stroke.
Methods: In a cohort of 231 acute ischemic stroke patients, we measured dehydroepiandrosterone (DHEA), DHEA-Sulfate
(DHEAS), cortisol at baseline and 30 minutes after stimulation with 1 ug ACTH. Delta cortisol, the amount of rise in the 1 ug
ACTH-test, was calculated. Primary endpoint was poor functional outcome defined as modified Rankin scale 3–6 after 1 year.
Secondary endpoint was nonsurvival after 1 year.
Results: Logistic regression analysis showed that DHEAS (OR 1.21, 95% CI 1.01–1.49), but not DHEA (OR 1.01, 95% CI 0.99–
1.04), was predictive for adverse functional outcome. Neither DHEA (OR 0.99, 95% CI 0.96–1.03) nor DHEAS (OR 1.10, 95% CI
0.82–1.44) were associated with mortality. Baseline and stimulated cortisol were predictive for mortality (OR 1.41, 95% CI
1.20–1.71; 1.35, 95% CI 1.15–1.60), but only basal cortisol for functional outcome (OR 1.20, 95% CI 1.04–1.38). Delta cortisol
was not predictive for functional outcome (OR 0.86, 95% CI 0.71–1.05) or mortality (OR 0.92, 95% CI 0.72–1.17). The ratios
cortisol/DHEA and cortisol/DHEAS discriminated between favorable outcome and nonsurvival (both p,0.0001) and
between unfavorable outcome and nonsurvival (p = 0.0071 and 0.0029), but are not independent predictors for functional
outcome or mortality in multivariate analysis (adjusted OR for functional outcome for both 1.0 (95% CI 0.99–1.0), adjusted
OR for mortality for both 1.0 (95% CI 0.99–1.0 and 1.0–1.01, respectively)).
Conclusion: DHEAS and the cortisol/DHEAS ratio predicts functional outcome 1 year after stroke whereas cortisol levels
predict functional outcome and mortality.
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Introduction
Stroke is the third-leading cause for disability worldwide [1]
with an incidence of about 500 per 100’000 persons at the age of
60 and a disease-related mortality of 20% [2].Therefore, early risk
stratification for an optimized allocation of health care resources is
warranted.
Activation of the hypothalamo-pituitary-adrenal (HPA)-axis has
been shown in various acute critical illnesses [3,4]. It is one of the
first measurable physiological responses to cerebral ischemia [5–8]
and cortisol levels are predictive of functional outcome in acute
stroke [9–11]. Besides cortisol, dehydroepiandrosterone (DHEA)
and its sulfate (DHEAS) are also released during HPA-activation.
DHEAS is the most abundant steroid of the adrenals. Under
healthy condition, DHEA secretion is synchronized with cortisol in
response to corticotrophin-releasing hormone and ACTH [12,13].
A dysbalance or inadequate stress response with down-regulation
of DHEAS is associated with an unfavorable outcome in severe
critical illness, severe sepsis and septic shock in some, but not all
studies [14–16].
PLOS ONE | www.plosone.org 1 May 2013 | Volume 8 | Issue 5 | e63224
DHEAS has antiglucocorticoid activity, neuroprotective and
antiatherosclerotic properties [17–22]. In rodents, synthesis of
DHEA and DHEAS has been shown in the brain [23–25]. In
addition, central nervous system DHEA production seems to
influence peripheral DHEA and DHEAS levels [26]. In longitu-
dinal studies, an increased cortisol/DHEAS ratio has been found
to accelerate atherosclerosis-related diseases [27] and to be
predictive for cardiovascular diseases [28] and all-cause-mortality
[29]. In chronic stress [30] and neurodegenerative diseases [31–
33], higher cortisol and lower serum DHEA and DHEAS values
with a consecutive higher cortisol/DHEAS-ratio have been found.
In the acute setting, high cortisol and an increased cortisol/
DHEAS – ratio upon admission is associated with severity of
illness in intensive care patients [34], corresponding to an
impaired adrenal androgen action [35].
In acute ischemic stroke, only two studies so far investigated the
predictive role of serum DHEAS, with controversial findings; one
[5] did not find a significant correlation between DHEAS and
functional outcome. The other study including only women found
a significant association between DHEAS and functional outcome
[36].
In critical illness, an impairment of secretion of basal cortisol
and the corticosteroid response to ACTH, is a highly debated
topic [37], but few and conflicting data exist in stroke about the
predictive value of the ACTH-test [38,39]. In view of the
controversial findings about DHEA, DHEAS and the low-dose
(1 mg) ACTH-test as outcome predictors in ischemic stroke, we
herein evaluated the predictive value of adrenal function testing in
a cohort of prospectively recruited stroke patients [8] by measuring
DHEA, DHEAS, basal and stimulated cortisol levels.
Subjects and Methods
Study Design and Setting
The study design of this prospective cohort study has been
described in detail [8]. From November 2006 to November 2007,
consecutive patients presenting with acute ischemic stroke were
enrolled. Informed consent was obtained from the patient if
possible, otherwise from a legal representative. This study adhered
to the consolidate standards for the reporting of observational
trials [40] and was accepted by the local ethics committee.
Patients, Clinical Variables, Blood Sampling and Cerebral
Imaging
Patients were eligible for inclusion into the original study [8] if
they were admitted to the emergency department with an acute
ischemic stroke defined according to World Health Organization
criteria [41] and with symptom onset within 72 hours. For the
purpose of this analysis, we included only patients in whom a low-
dose-ACTH- test (Synacthen) had been performed on day 1 (i.e.
the first morning after admission) according to study protocol and
a remaining serum sample was available from the same day. Delta
cortisol was calculated as the difference between basal and
stimulated cortisol level.
Vital signs, relevant comorbidities, medication before stroke,
risk factors, family history and severity of stroke assessed by The
National Institutes of Health Stroke Scale (NIHSS) score were
assessed on admission. Cerebral computed tomography (CCT)
was performed in all patients on admission mainly to exclude
intracranial hemorrhage. Thereafter, MRI was performed on a
clinical 1.5-Tesla MR Avanto system (Siemens, Erlangen,
Germany) using a stroke protocol, including T1-, T2-, and
diffusion-weighted imaging (DWI) sequences, and a magnetic
resonance angiography. MRI with DWI was available in 137
stroke patients (59%). In those patients, DWI lesion volumes were
determined by consensus of two experienced raters unaware of the
clinical and laboratory results.
The clinical stroke syndrome was determined applying the
criteria of the Oxfordshire Community Stroke Project, that is, total
anterior circulation syndrome (TACS), partial anterior circulation
syndrome (PACS), lacunar syndrome (LACS),and posterior
circulation syndrome (POCS) [42].
Hypothesis and Endpoints
We hypothesized that activation of the HPA-axis with
consecutive dysbalance of adrenal steroids is associated with
functional outcome and mortality in acute stroke, similar to the
associations seen in critical illness.
The primary endpoint was poor functional outcome defined as
a modified Rankin scale (mRS) of 3–6 points [43]. The secondary
endpoint was death (mRS=6). Both endpoints were assessed by
structured telephone interviews with the patient, relatives and/or
treating primary care physician one year after the index event.
Assays
Blood samples were obtained from an indwelling venous
catheter between 7 and 8 a.m. in the morning after admission.
Plasma was collected at the time of blood sampling in both native
plastic tubes and containing ethylenediaminetetraacetic acid
(EDTA). The tubes were centrifuged at 3000 g, and plasma was
stored at –70uC until assayed.
DHEA (ng/mL) was measured by ELISA-Assay (IBL Interna-
tional GmbH, Hamburg, Germany). with an assay range between
0–30 ng/mL.For better comparison and calculation, DHEA
values were converted to nmol/L.
DHEAS (micromol/L) was measured by ElectroChemiLumi-
nescence (ECL) cobas 6000 analyzer (Roche Diagnostics, Basel,
Switzerland) with an assay range between 0.003–27.0 micromol/
L.
1 microgram ACTH-stimulation tests were performed using
0.25 mg tetracosactidum (0.250 mg/mL synthetic ACTH1–24,
Synacthen, Novartis Pharma, Switzerland) divided into
0.001 mg tetracosactidum doses by the pharmacy of the Univer-
sity Hospital Basel (Basel, Switzerland), as described [3,44]. In all
subjects, blood samples were taken at 0 min. for the basal
measurement of cortisol and again at 30 min. for the measurement
of serum cortisol concentration after intravenous (iv) administra-
tion of 1 microgram ACTH.
Cortisol was measured with a competitive chemiluminescence-
immunoassay (IMMULITE 2000; Siemens Medical Solution
Diagnostics, Los Angeles, USA), which has a sensitivity of 0.02
microgram/mL with an intra-assay coefficient of variation of 6.8%
to 9.0%.
Statistical Analysis
Discrete variables are expressed as percentage and continuous
variables as medians and interquartile ranges (IQR) or as mean
with standard deviation (SD) based on the distribution of the data.
Two group comparisons of not normally distributed data were
made using the Mann-Whitney U test. Spearman’s Rank
Correlation was used for calculating correlations. For multi-group
comparisons Kruskal-Wallis was used as a global test.
As a parameter of adrenal dissociation between cortisol and
DHEA(S) synthesis, the ratios cortisol/DHEA and cortisol/
DHEAS were calculated. To test whether the values of DHEA,
DHEAS, cortisol, stimulated cortisol 30 minutes after ACTH, and
delta cortisol are associated with poor functional outcome or
survival, we calculated a logistic regression analysis adjusted by
Adrenal Function in Acute Ischemic Stroke
PLOS ONE | www.plosone.org 2 May 2013 | Volume 8 | Issue 5 | e63224
age, gender and comorbidities using the Charlson Index [45].
Time to last follow-up, death or re-event was analyzed in Kaplan-
Meier curves. The three groups ‘‘good outcome’’ corresponding to
an mRS of 0–2, ‘‘poor outcome but survival’’ corresponding to an
mRS of 3–5 and ‘‘non-survival’’, corresponding to an mRS of 6,
were also compared.
Due to the known influence of age and gender on DHEAS and
DHEA levels [46–48], we assessed the effects of age and gender.
Age classes were defined by decades ,60 y, 60–69 y, 70–79 y,
and .80 y.
All testing was 2-tailed and the significance level was defined as
p,0.05 or, if comparing 3 groups, p,0.016. For all calculations,
STATA 9.2 (Stata Corp, College Station,TX, USA) and
GraphPad Prism 5.0 (La Jolla, Ca, USA) were used.
Results
Baseline Characteristics
Of the original 362 ischemic stroke patients, 231 had both an
available serum sample and a low-dose ACTH at day 1 after
admission and were thus eligible for this analysis. Baseline
characteristics of the analyzed and the original sample were
similar (data not shown). The median NIHSS on admission was 5
(IQR 2–10). 37% (86 patients) had an unfavorable functional
outcome (i.e. mRS .2) after 1 year, and all-cause-mortality after 1
year was 17.0% (38 patients). Baseline characteristics are shown in
Table 1.
9 patients (3.9%) were on an oral glucocorticoid treatment on
admission; their levels of DHEA, basal and stimulated cortisol
were lower (p = 0.0027, 0.0267, 0.0423) as compared to patients
without glucocorticoid treatment, whereas the levels of DHEAS
(p = 0.0548), delta cortisol (p = 0.6) and the ratios cortisol/DHEA
(p= 0.7) and cortisol/DHEAS (p= 0.9) were not different in
patients with glucocorticoid treatment compared to patients
without glucocorticoid treatment. 27 patients (11.7%) were on
benzodiazepine medication; their levels of stimulated and delta
cortisol were higher (p = 0.0053 and 0.0052), whereas DHEA
(p= 0.8), DHEAS (p = 0.4), basal cortisol (p = 0.4) and the ratios
cortisol/DHEA (p= 0.7) and cortisol/DHEAS (p= 0.1) did not
differ between patients with and without benzodiazepine medica-
tion. 4 patients (1.7%) were on antiepileptic treatment, 4 (1.7%)
had tricyclic antidepressants, 2 (0.9%) had opiate analgetics,
whereas dopamine antagonists and haloperidol were taken by only
one patient (0.4%).
Of the 131 patients with incomplete data that were not included
in this analysis, 13 were lost to follow-up, 54% had an mRS .2
and thus an unfavourable outcome after 1 year, and mortality after
1 year in these patients was 22%. Lost to follow-up of the patients
qualifying for this analysis was 3% or 7 patients.
Median baseline DHEA, DHEAS, basal cortisol, stimulated
cortisol after 30 minutes and delta cortisol were 15.5 nmol/L
(IQR 9.4–25.0), 2.4 umol/L (IQR 1.3–3.7), 475 nmol/L (IQR
337–611), 742 nmol/L (619.5–859.5) nmol/L, and 257 nmol/L
(IQR 156.5–376), respectively.
Gender and Age Differences
Overall gender differences were found in DHEA (p= 0.0047),
which was higher in women, and DHEAS (p= 0.0002), which was
higher in men. Neither basal (p = 0.4801), stimulated (p = 0.0572),
delta cortisol (p = 0.5220) nor cortisol/DHEA (p= 0.8138) showed
significant gender differences.
A decrease of DHEAS across age classes was found both in men
(p,0.0001) and women (p = 0.0015), which lead to an increase of
the cortisol/DHEAS - ratio across age classes (women: p = 0.0036,
men: p,0.0001).
Correlation between Stroke Severity and Adrenal
Function
Basal and stimulated cortisol correlated with severity of stroke as
assessed by NIHSS (correlation coefficient 0.36 (p,0.0001) and
0.32 (p,0.0001). The ratios cortisol/DHEA and cortisol/DHEAS
showed a weaker correlation (correlation coefficient 0.16, p = 0.02
and 0.15, p = 0.02). There was no significant correlation between
NIHSS and delta cortisol, as well as DHEA and DHEAS.
Adrenal Function and Functional Outcome
Before adjusting for covariates, DHEAS, and to a lesser extent
DHEA, were associated with functional outcome (p= 0.0212 and
Table 1. Baseline characteristics.
Age, yr (mean 6 SD) 71614
Male sex, no (%) 137 (59%)
Clinical findings mean 6 SD
body temperature, uC 37.060.7
Heart rate, beats/min 78616.69
systolic blood pressure, mmHg 161626.24
diastolic blood pressure, mmHg 91616
Medication upon admittance
Diuretics 80 (35%)
ACE-inhibitors 53 (23%)
Sartans 43 (19%)
Ca-antagonists 31 (13%)
Betablockers 58 (25%)
Statins 50 (22%)
Phenprocoumon 21 (19%)
Acetyl salicylate 100–300 mg daily 86 (37%)
Benzodiazepines 27 (11.7%)
Glucocorticoids 9 (3.9%)
Clinical Stroke Syndrome
TACS 22 (10%)
PACS 106 (46%)
LACS 48 (21%)
POCS 55 (24%)
Scores median (IQR)
NIHSS on admission (pts) 5 (2–10)
Charlson Comorbidity Index (pts) 1 (0–2)
Laboratory findings median (IQR)
Cortisol basal (nmol/L) 475 (337–611)
Cortisol 30 min. (nmol/L) 742 (619.5–859.5)
D Cortisol (nmol/L) 257 (156.5–376)
DHEA (nmol/L) 15.5 (9.4–25.0)
DHEAS (mmol/L) 2.4 (1.3–3.7)
Outcome
death after 1 year, no. (%) 38 (16.45)
Lost to follow-up after 1 year, no. (%) 7 (3)
n = 231.
doi:10.1371/journal.pone.0063224.t001
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p= 0.0744). Basal and stimulated cortisol, but not delta cortisol,
were also associated with functional outcome (p= 0.0013, 0.0389,
and 0.4996, respectively). The ratios cortisol/DHEA and cortisol/
DHEAS were also associated with functional outcome (p= 0.0047
and 0.0002).
After adjusting for age, gender and the Charlson Index, results
remained largely unchanged except the ratios cortisol/DHEA and
cortisol/DHEAS.
DHEAS, but not DHEA, was predictive for poor functional
outcome (adjusted OR 1.21 (95% CI 1.01–1.49, and 1.01 (0.99–
1.04), respectively). Basal cortisol remained predictive for func-
tional outcome (adjusted OR 1.20 (95% CI 1.04–1.38), whereas
stimulated cortisol and delta cortisol did not have any predictive
value (adjusted OR 1.11 (95% CI 0.97–1.27 and 0.86 (0.71–1.05),
respectively). The ratios cortisol/DHEA and cortisol/DHEAS
were not predictive for functional outcome (adjusted OR for both
1.0 (95% CI 0.99–1.0).
For detailed values, see Table 2.
Adrenal Function and Mortality
Before adjusting for covariates, DHEAS, but not DHEA, was
associated with all-cause-mortality after 1 year (p = 0.0709 and
0.0477, respectively). Basal and stimulated cortisol, but not delta
cortisol, were also associated with mortality (p,0.0001,
p = 0.0013, and p= 0.3232, respectively). The ratios cortisol/
DHEA and cortisol/DHEAS were associated with mortality as
well (p = 0.0001 and 0.0003).
After adjusting for age, gender and the Charlson Index, neither
DHEA nor DHEAS remained predictive for mortality (adjusted
OR 0.99 and 1.10 (95% CI 0.96–1.03 and 0.82–1.44). Basal and
stimulated cortisol, but not delta cortisol, were predictive for
mortality (adjusted OR 1.41 (95% CI 1.20–1.71), 1.35 (95% CI
1.15–1.60), and 0.92 (95% CI 0.72–1.17), respectively.) The ratios
cortisol/DHEA and cortisol/DHEAS were not predictive for
mortality (adjusted OR for both 1.0 (95% CI 0.99–1.0 and 1.0–
1.01, respectively). For detailed results, see Table 3.
Overall survival was better in patients with a basal cortisol level
below the median of 475 nmol/L (p= 0.001, Hazard Ratio (HR)
0.35, 95% CI 0.19–0.67; Figure 1A) and with a stimulated cortisol
level below the median of 742 nmol/L (p = 0.02, HR 0.45, 95%
CI 0.24–0.86, Figure 1B). Overall survival was better in patients
with a DHEA level above the median level of 15.5 nmol/L
(p = 0.0236, Hazard Ratio 2.09, 95% CI 1.104 to 3.955;
Figure 1C). DHEAS survival was not significant (p = 0.1490,
Hazard Ratio 1.60, 95% CI 0.85–3.80; Figure 1D). Overall
survival was better in patients with a cortisol/DHEA ratio below
the median of 27 nmol/nmol (p = 0.0002, Hazard Ratio 0.32,
95% CI 0.17–0.61; Figure 1E) and with a cortisol/DHEAS ratio
below the median of 203 nmol/micromol (p = 0.0004, Hazard
Ratio 0.31, 95% CI 0.17–0.59; Figure 1F).
The area under the curve (AUC) was best for basal cortisol and
cortisol/DHEAS with 0.71 (95% CI 0.61–0.80 for basal cortisol
and 0.63–0.81 for cortisol/DHEAS), followed by cortisol/DHEA
(AUC 0.70, 95% CI 0.61–0.79), stimulated cortisol (AUC 0.67,
95% CI 0.57–0.77), DHEAS (AUC 0.60, 95% CI 0.51–0.69), and
DHEA (AUC 0.59, 95% CI 0.49–0.69) (see figure 2).
‘‘Poor Outcome but Survival’’ Compared to Non-survival
We found an overall difference between the groups mRS 0–2
(‘‘good outcome’’), mRS 3–5 (‘‘poor outcome but survival’’) and
mRS 6 (‘‘non-survival’’) for basal cortisol (p = 0.0002), stimulated
cortisol (p = 0.0041) and the ratios cortisol/DHEA (p= 0.0003)
and cortisol/DHEAS (p,0.0001).
For basal cortisol, there was only a difference between mRS 0–2
and mRS 6 (p= 0.0010) but not between mRS 3–5 and mRS 6.
For stimulated cortisol, a difference was found between mRS 0–
2 and mRS 6 (p = 0.0010) and between mRS 3–5 and mRS 6
(p = 0.0112).
For the ratio cortisol/DHEA and cortisol/DHEAS, we found
differences between mRS 0–2 and mRS 6 (both p,0.0001) and
between mRS 3–5 and mRS 6 (p= 0.0071 and p=0.0029).
Clinical Stroke Syndrom, Lesion Size and Andrenal
Parameters
Values of basal cortisol showed significant differences with
highest values in TACS and lowest in PACS (p= 0.002);
stimulated cortisol was highest in PACS, lower in LACS
(p = 0.0002) and lowest in POCS (p= 0.0002). DHEA, DHEAS
and their ratios with cortisol did not depend on the subtype of
stroke according to the Oxfordshire Community Stroke Project
criteria (all p.0.1).
Lesion size correlated with basal (correlation coefficient 0.36,
p = 0.0361) and stimulated cortisol (correlation coefficient 0.32,
p = 0.0027) and cortisol/DHEA (correlation coefficient 0.15,
p = 0.0289) as well, but not with delta cortisol (p = 0.28), DHEA
(p= 0.27), DHEAS (p= 0.26), or cortisol/DHEAS (p= 0.74).
Discussion
Acute ischemic stroke activates the HPA-axis [6,49], and the
role of adrenal function as outcome predictor is debated
[5,6,36,38,39].
Table 2. Prognostic value of DHEA, DHEAS, basal cortisol, stimulated, delta cortisol, and the ratios cortisol/DHEA and cortisol/
DHEAS for functional outcome after 1 year.
Functional outcome mRS 2 or less,median (IQR) mRS.2,median (IQR) Adjusted* OR, (95% CI)
DHEA(nmol/L) 16.9(10.7–26.2) 14.0(8.4–23.2) 1.01(0.99–1.04)
DHEAS(micromol/L) 2.7(1.2–4.0) 2.0(1.3–2.8) 1.23(1.01–1.49)
Cortisol(nmol/L) 452.5(323–569) 511.5(372.3–680) 1.20(1.04–1.38)
Stimulated Cortisol(nmol/L) 731(623–837) 774(641–911) 1.11(0.97–1.27)
Delta cortisol(nmol/L) 267.5(169.8–384) 247.5(141–374) 0.86(0.71–1.05)
Cortisol/DHEA (nmol/nmol) 24 (16–35) 31 (19–60) 1.0 (0.99–1.00)
Cortisol/DHEAS (nmol/micromol) 171 (113–296) 248 (169–433) 1.0 (0.99–1.00)
*adjusted for gender, age and charlson index.
doi:10.1371/journal.pone.0063224.t002
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In our study, DHEAS but not its precursor DHEA was
associated with functional outcome, but not with survival. The
different result for DHEA and DHEAS is most likely due to the
short serum half-life, and the pronounced intraindividual and
interindividual variability of DHEA.
Previous observations in patients with community-acquired
pneumonia, septic shock, critical illness and trauma found a
predictive value of high DHEAS levels for both favorable [14–
16,50] and unfavorable outcome [15,16,51]. So far, only two
studies investigated DHEAS levels in stroke, again with contro-
versial findings. One study did not find any correlation between
DHEAS levels and functional outcome [5], whereas the other
found a significant association with functional outcome but not
with mortality in a population of postmenopausal women [36]. In
some, but not all [52] epidemiologic studies, low DHEAS-levels
were predictive for intima-media-thickness [53,54], cardiovascular
disease [28,55] and all-cause mortality [29,56,57]. In rats, DHEA
has been shown to have a direct local neuroprotective effect in
ischemia if administered in the right time window [58], indicating
a local neuroprotective effect of systemic DHEA/2S. Low
DHEA/2S levels may therefore represent a lack of neuroprotec-
tion and/or vascular protection.
Although acute ischemic stroke is considered an acute critical
illness, findings from other critical illnesses concerning DHEA and
DHEAS may not translate into the field of ischemic stroke. DHEA
and DHEAS are also synthesized locally in the brain [23] and
peripheral DHEA- and DHEAS-levels may be influenced by brain
DHEA/2S synthesis [59,60].
In our patients, we found that low DHEAS levels predicted
adverse functional outcome. This finding is in agreement with the
assumed neuroprotective role of DHEAS in ischemic stroke[20–
22]. It may be that lower DHEAS synthesis leads to a higher
ischemic neuronal loss after stroke and thus unfavorable outcome.
Our data showing a significant association of DHEAS and
outcome can, however, not answer the question whether lower
DHEAS is a cause or a consequence of ischemic stroke, or a
combination of both. An increased cortisol/DHEAS ratio has
been identified as a risk factor for atherosclerosis [26,27].
Therefore, DHEAS and cortisol/DHEAS ratio upon admittance
may represent the values to which the patient was exposed before
stroke pointing to a potential causal factor of stroke. On the other
hand, DHEAS and cortisol/DHEAS ratio may represent the acute
activation of the HPA-axis during or after stroke and could
therefore be the consequence of the stroke.
In accordance with previous literature, basal cortisol is a
predictor for mortality and functional outcome in patients with
ischemic stroke in our cohort, with higher levels in patients with an
unfavorable outcome [5–9,38]. High basal cortisol reflects an
activated HPA-axis and a higher stress level. Stimulated cortisol is
a measure of adrenal reserve. In our study, basal cortisol was a
stronger predictor for outcome and mortality than stimulated
cortisol levels.
As basal and stimulated cortisol levels are correlated with the
NIHSS, it is suggestive that the amount of activation of the HPA-
axis is at least partially a result of the acute ischemic event. This is
also supported by the correlation of lesion size with cortisol values.
Furthermore, delta cortisol was not associated with functional
outcome or mortality. Most probably, this is due to the high
variability of the cortisol surge and due to the fact that some of the
patients are already maximally stimulated by physical stress [61].
A critical illness-related corticosteroid insufficiency (CIRCI), as
described and controversially debated in intensive care patients
[62], is defined by a relatively low basal cortisol or an insufficient
increase after ACTH stimulation and associated with a higher
mortality in septic shock [63,64]. According to our data, the
amount of cortisol increase upon ACTH stimulation seems not to
be relevant and predictive in stroke. This is in accordance with
data of ACTH stimulation in severe pneumonia [65]. Whereas
early activation of the HPA-axis at a hypothalamic level has been
shown to be predictive for functional outcome and survival in
acute ischemic stroke and is easily measurable [8,66], the adrenal
reaction is more subtle. The prognostic value of DHEAS and
cortisol for functional outcome shows that acute ischemic stroke
with unfavorable outcome is a state in which the HPA-axis and the
adrenals as its end-organs react with a relatively higher synthesis of
cortisol in comparison to DHEAS, leading to a higher cortisol/
DHEAS ratio than in patients with favourable outcome. At the
level of the adrenals, this means a shift from synthesis of androgen
precursor hormones, which the body apparently does not need for
imminent survival, to synthesis of a stress hormone thought to be
essential for survival in acute illness. Accordingly, there was a
gradual increase of the ratios cortisol/DHEA and cortisol/
DHEAS from good outcome to poor functional outcome to non-
survival. The ratio cortisol/DHEAS had the same AUC like basal
cortisol (see figure 2) and a lower hazard ratio (see figure 1), being
as sensitive for mortality in acute ischemic stroke as basal cortisol
in univariate but not multivariate analysis.
An increased cortisol/DHEAS ratio has been found to be a
surrogate for neurodegenerative diseases[31–33]. Therefore, an
alternative hypothesis is that the cortisol/DHEAS ratio may
represent a slightly lower cerebral DHEAS production in relation
to cortisol already before the stroke in predisposing patients.
Table 3. Prognostic value of DHEA, DHEAS, basal cortisol, stimulated cortisol, delta cortisol, and the ratios cortisol/DHEA and
cortisol/DHEAS for mortality after 1 year.
Mortality survivors, median (IQR) Nonsurvivors, median (IQR) Adjusted* OR, (95% CI)
DHEA (nmol/L) 15.9 (9.9–25.5) 12.1 (8.2–22.8) 0.99 (0.96–1.03)
DHEAS (micromol/L) 2.5 (1.3–3.9) 1.9 (1.2–2.8) 1.10 (0.82–1.44)
Cortisol (nmol/L) 461 (325–585) 606 (471–800) 1.41 (1.20–1.71)
Stimulated Cortisol (nmol/L) 728 (618–841) 836 (691–1078) 1.35 (1.15–1.60)
Delta cortisol (nmol/L) 261 (164–380) 241 (139–369) 0.92 (0.72–1.17)
Cortisol/DHEA (nmol/nmol) 16 (16–37) 190 (117–304) 1.0 (1.0–1.01)
Cortisol/DHEAS (nmol/micromol) 46 (27–78) 389 (233–582) 1.0 (0.99–1.00)
*adjusted for gender, age and charlson index.
doi:10.1371/journal.pone.0063224.t003
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Figure 1. Kaplan Meier Survival Curves. A. Survival in relation to median cortisol level of 475 nmol/L. p = 0.0014, Hazard Ratio 0.35, 95% CI 0.19–
0.67. B. Survival in relation to median stimulated cortisol level of 742 nmol/L. p = 0.015, Hazard Ratio 0.4496, 95% CI 0.24–0.86. C. Survival in relation
to median dehydroepiandrosterone level of 15.5 nmol/L. p = 0.0236, Hazard Ratio 2.09, 95% CI 1.104 to 3.955. D. Survival in relation to median
dehydroepiandrosterone-sulfate level of 2.4 umol/L. p = 0.1490, Hazard Ratio 1.60, 95% CI 0.85–3.80. E. Survival in relation to median cortisol/DHEA
level of 27 nmol/nmol. p = 0.0002, Hazard Ratio 0.32, 95% CI 0.17–0.61. F: Survival in relation to median cortisol/DHEAS level of 203 nmol/micromol.
p = 0.0004, Hazard Ratio 0.31, 95% CI 0.17–0.59.
doi:10.1371/journal.pone.0063224.g001
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Although we found a predictive value for outcome and mortality
for the cortisol/DHEAS-ratio in univariate analysis, it did not
remain after adjustment, moreover DHEAS itself was only
predictive for outcome and not for survival.
There are several limitations to this study.
First, we performed single measurements of adrenal hormones
upon admission to the hospital. This bears a potential for bias, as
cortisol, DHEA, DHEAS and the adrenal reactivity to the ACTH
test has a certain diurnal and individual variability and may
change fast in relation to external stimuli. Repeated measurements
and urinary collection may further improve the prognostic ability
of hormones for outcome prediction. Yet, previous studies have
shown that initial hormone measurements predict outcome in
acute illness and are easier to collect on an everyday basis [67,68],
whereas in chronic illnesses and neurodegenerative processes [69–
72], measurement of urinary excretion of steroid metabolites has
proven to be more feasible and useful.
Second, we did not collect specimen in patients before stroke
onset. Therefore, we cannot differentiate between baseline
abnormalities and acute changes due to the event itself.
Third, a second measurement of adrenal hormones at the time
of follow-up would have permitted some insights in the long term
dynamics of these markers. However, this has not been performed
due to limited resources.
Fourth, with our data, it is not possible to discriminate between
adrenal and cerebral synthesis of DHEA. Since in stroke patients
we do not routinely perform spinal taps we have no means of easily
assessing potential possible intra-cerebral production of DHEAS.
Finally, whereas we collected detailed data on drugs which are
known to be associated with stroke prognosis like antihypertensive
drugs and statins, we have only limited knowledge on medication
with potential influence on adrenal function. However, by
adjusting to the Charlson Index, the data is adjusted to
comorbidities like dementia, diabetes, hemato-oncologic diseases
and connective tissue disease that have the potential to influence
adrenal function directly or via concomitant medication.
Conclusions
This study found that surrogates of adrenal androgen and
glucocorticoid production are predictive for functional outcome
and mortality in acute ischemic stroke. DHEAS is predictive for
functional outcome only, whereas cortisol levels are predictive of
both, functional outcome and mortality. An increased cortisol/
DHEAS ratio is associated with an unfavourable outcome, in uni-
but not in multivariate analysis. The low-dose-ACTH-test does not
add any additional prognostic information. CIRCI, a term
controversially discussed in critical illness, is apparently not of
clinical relevance in acute stroke.
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